US health agency releases 2026 quality ratings for Medicare plans

The U.S. government announced 2026 Medicare quality ratings, which are critical for determining bonus payments to health insurers and will impact their 2027 revenues. CVS Health's Aetna unit demonstrated strong performance with over 81% of its members in top-rated (4+ star) plans, followed by UnitedHealth at 78%, Elevance at 55% (a significant increase from 40% last year), and Humana at approximately 20%. These ratings, largely in line with analyst expectations due to prior company announcements, highlight the varying competitive positions and financial outlooks for major players in the Medicare Advantage market.

Analysis

The U.S. government has released its 2026 Medicare Advantage quality ratings, which are crucial as they directly determine bonus payments to health insurers and will significantly impact their 2027 revenues. These ratings, ranging from one to five stars, assess factors like customer satisfaction and access to care, with higher ratings translating to substantial financial incentives. Oppenheimer analysts noted these results were largely anticipated due to prior company pre-announcements.

CVS Health's Aetna unit demonstrated strong performance, with over 81% of its members in top-rated (4+ star) programs, including 63% in 4.5-star plans for next year, indicating a robust competitive position. UnitedHealth also performed well, securing 78% of its members in 4-star or higher plans, with 40% in 4.5-star plans. In contrast, Humana reported approximately 20% of its members in high-rated plans, positioning it at the lower end among major players.

Elevance emerged as a significant gainer, increasing its membership in 4-star and higher plans to 55% from 40% a year ago, reflecting notable operational improvements. Overall, 64% of Medicare Advantage members are now covered by plans rated four or five stars, underscoring a general trend towards higher quality within the sector. Centene's Wellcare also expressed satisfaction with its continued progress in the ratings.

Key Decisions for Investors

• Investors should consider re-evaluating positions in health insurers based on the newly released Medicare Advantage star ratings, focusing on companies demonstrating strong performance, particularly CVS Health and Elevance, given their high ratings and Elevance's significant year-over-year improvement. It would be prudent to monitor the impact of these ratings on 2027 revenues, as higher star ratings directly correlate with increased bonus payments and potential market share gains. Conversely, investors should exercise caution with Humana due to its comparatively lower percentage of highly-rated plans, which may signal headwinds for future bonus payment growth.